BRIEF published on 06/10/2026 at 20:18, 1 month 5 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 1 month 5 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 1 month 5 days ago Poxel nomme Yves Decadt comme nouveau Directeur Général Partenariats Stratégiques Biopharmaceutique Plan De Continuation Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 1 month 5 days ago Poxel nomme Yves Decadt PDG pour faire progresser ses objectifs stratégiques Partenariats Stratégiques Biopharmaceutique Poxel Iméglimine Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 1 month 5 days ago Informations privilégiées / Autres communiqués Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques. Continuité et ambition commerciale confirmée Partenariats Poxel PXL065 Iméglimine Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 1 month 5 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 3 months 15 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 3 months 15 days ago Poxel cède le PXL770 à Scynexis pour une valeur potentielle de 196 millions de dollars Accord Financier Poxel PXL770 SCYNEXIS Polykystose Rénale
BRIEF published on 03/31/2026 at 13:12, 3 months 15 days ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 3 months 15 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
Published on 07/16/2026 at 00:40, 4 hours 7 minutes ago Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Published on 07/15/2026 at 23:00, 5 hours 47 minutes ago Battery X Metals Completes First-Generation Proprietary Battery Adaptor for Tesla Model 3 and Model Y, Marking a Significant Commercial Readiness Milestone for its Patent-Pending Lithium-Ion Battery Rebalancing Platform
Published on 07/15/2026 at 22:45, 6 hours 2 minutes ago Mako Mining Announces Q2 2026 Production Results with Record Gold Sold of 14,610 Au oz., Revenues of ~US$63 Million and Cash and Securities Balance of US$112 Million
Published on 07/15/2026 at 22:15, 6 hours 32 minutes ago Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call
Published on 07/15/2026 at 14:30, 14 hours 17 minutes ago Avant Brands Reports Q2 2026 Results Highlighted by 34% Growth in Recreational Revenue
Published on 07/16/2026 at 01:01, 3 hours 45 minutes ago EQS-Adhoc: Circus Adjusts FY2026 Financial Guidance; Sharpens Focus on Operational Scalability
Published on 07/15/2026 at 20:14, 8 hours 33 minutes ago EQS-Adhoc: Bajaj Mobility AG: Preliminary figures for Q2 / 2026
Published on 07/15/2026 at 19:42, 9 hours 4 minutes ago EQS-Adhoc: Cherry SE: Adjusted EBITDA for the first half of 2026 significantly above prior-year operating result
Published on 07/15/2026 at 18:28, 10 hours 18 minutes ago Vulcan receives initial strategic funding for Lionheart Project
Published on 07/15/2026 at 17:45, 11 hours 2 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2026
Published on 07/15/2026 at 17:45, 11 hours 2 minutes ago Half yearly report on the liquidity contract
Published on 07/15/2026 at 17:45, 11 hours 2 minutes ago Nombre total de droits de vote et actions composant le capital social au 30 juin 2026
Published on 07/15/2026 at 17:40, 11 hours 7 minutes ago Déclaration des transactions sur actions propres réalisées du 8 au 14 juillet 2026
